JP5828638B2 - 満腹活性を有する魚類タンパク質の加水分解産物、該加水分解産物を含む栄養補助食品及び医薬品の組成物、及び、その製造方法。 - Google Patents
満腹活性を有する魚類タンパク質の加水分解産物、該加水分解産物を含む栄養補助食品及び医薬品の組成物、及び、その製造方法。 Download PDFInfo
- Publication number
- JP5828638B2 JP5828638B2 JP2010545508A JP2010545508A JP5828638B2 JP 5828638 B2 JP5828638 B2 JP 5828638B2 JP 2010545508 A JP2010545508 A JP 2010545508A JP 2010545508 A JP2010545508 A JP 2010545508A JP 5828638 B2 JP5828638 B2 JP 5828638B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- hydrolyzate
- fish
- fish protein
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010028690 Fish Proteins Proteins 0.000 title claims description 31
- 238000006460 hydrolysis reaction Methods 0.000 title claims description 16
- 230000007062 hydrolysis Effects 0.000 title claims description 12
- 230000036186 satiety Effects 0.000 title claims description 9
- 235000019627 satiety Nutrition 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000000694 effects Effects 0.000 title description 11
- 235000015872 dietary supplement Nutrition 0.000 title description 4
- 239000000047 product Substances 0.000 title description 3
- 239000003531 protein hydrolysate Substances 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 230000028327 secretion Effects 0.000 claims description 24
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 20
- 238000009826 distribution Methods 0.000 claims description 16
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 15
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 13
- 241000251468 Actinopterygii Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000011541 reaction mixture Substances 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 8
- 241000194108 Bacillus licheniformis Species 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 235000019465 surimi Nutrition 0.000 claims description 7
- 102000005593 Endopeptidases Human genes 0.000 claims description 6
- 108010059378 Endopeptidases Proteins 0.000 claims description 6
- 241001609028 Micromesistius poutassou Species 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 102100025841 Cholecystokinin Human genes 0.000 claims description 4
- 101800001982 Cholecystokinin Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229940107137 cholecystokinin Drugs 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 description 28
- 241000700159 Rattus Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 235000012631 food intake Nutrition 0.000 description 15
- 230000037406 food intake Effects 0.000 description 15
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 13
- 101710142157 Stanniocalcin-1 Proteins 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 9
- 235000019688 fish Nutrition 0.000 description 9
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 102400000921 Gastrin Human genes 0.000 description 5
- 108010052343 Gastrins Proteins 0.000 description 5
- 241001125048 Sardina Species 0.000 description 5
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 4
- 240000006439 Aspergillus oryzae Species 0.000 description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 4
- 241000252203 Clupea harengus Species 0.000 description 4
- 241000276438 Gadus morhua Species 0.000 description 4
- 241000276492 Melanogrammus Species 0.000 description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- 241000736062 Scomber scombrus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000353095 Coryphaenoides rupestris Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001125930 Trisopterus Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003158 enteroendocrine cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 241000269821 Scombridae Species 0.000 description 2
- 241000252496 Siluriformes Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241001504582 Trachurus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000020640 mackerel Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 101000701440 Homo sapiens Stanniocalcin-1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000276419 Lophius americanus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- -1 carbohydrate compounds Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 108010043649 gastrin I Proteins 0.000 description 1
- 102000038739 gastrin/cholecystokinin family Human genes 0.000 description 1
- 108091072364 gastrin/cholecystokinin family Proteins 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000005585 lifestyle behavior Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
Description
プタスダラ(ミクロメシスティウス・ポタソウ(Micromesistius poutassou))は北大西洋ニューファンドランドで釣られる。魚類は切り身に切り取られ、その後、そのすり身を得るためにすりつぶされる。この魚類のすり身は、加水分解産物を製造するためのタンパク質の供給源の構成要素となる。前記すり身は使用されるまで−20°Cで保管される。
% DH = [(B.NB)/(α.htot.MP)] * 100
得られたタンパク質の加水分解産物を構成しているペプチドの分子量を決定することが、立体排除クロマトグラフィー(SEC−HPLC)によって実施される。
サバ(H2)(スコムベル・スコムブルス(Scomber scombrus))、アジ(H3)(トラクルス属の複数種(Trachurus spp.))、コソダラ(H4)(コリファエノイデス・ルペストリス(Coryphaenoides rupestris))(図3)と、ビブ(bib)(H5)(トリソプテルス・エスマルキ(Trisopterus esmarki))、イワシ(H6)(サルディナ・ピルカルドゥス(Sardina pilchardus))、ニシン(H7)(クルペア・ハレングス(Clupea harengus))、パンガ(panga)(H8)、スリフォルメ(Suliforme)(図4)と、タイセイヨウマダラ(H9)(ガドゥス・モルア(Gadus morhua))、シロイトダラ(H10)(ポルラキウス・ヴィレンス(Pollachius virens))及びモンツキダラ(H11)(メラノグランムス・アレグレフィヌス(Melanogrammus aeglefinus))(図5)とのタンパク質の加水分解産物は実施例1の方法に従って調製された。加水分解産物それぞれを構成するペプチドの分子量分布は、実施例1で用いられたような同一方法に従って解析された。
前記タンパク質の加水分解産物H1に存在するCCKsに類似する分子が、RIAキット(GASK−PR、CISバイオインターナショナル、フランスバニョール/セズ)を用いる放射線免疫学的解析によって解析された(試験は3回実施された。)。CCKsに類似する分子は、ガストリン及びCCKに共通な8個のアミノ酸に対して特異的な抗体に固定することができる分子のいずれかを意味し、前記抗体は前述の解析で用いられた抗体である。ガストリン及びCCKsは、ペプチド配列のC末端で同一の該ペプチド配列を有する。
前記H1タンパク質の加水分解産物は、STC1腸内分泌細胞タイプでCCK分子と、GLP1との分泌を促進する能力について試験された。これは、消化管内分泌細胞によるCCK及びGLP1の分泌が、満腹現象を構成する主要なシグナルの1つを示すためである。STC−1細胞は、マウスの小腸から生じる腫瘍内分泌細胞由来の多数のホルモン産生細胞(plurihormonal cells)である。STC−1細胞は、CCKの特定の分泌を生じる現象の研究のための細胞モデル(Mangel AWら、Am J Physiol、1995.268(1 Pt 1):G90−4頁)及びGLP1の特定の分泌を生じる現象を研究するための細胞モデル(Brubaker PLら、Can J Diabetes.2003;27:141−148)として用いられる。
実施例1に従って得られたH1加水分解産物の性質は、ラットの食物摂取と、さまざまな血液パラメーターとで評価された。食物摂取での前記加水分解産物の満腹感を生じさせる効果を証明する目的は、内分泌生理学的パラメーターによって実証した。
個体8頭の4つのグループに分けられた、体重275ないし290グラムのウィスターラットの雄32頭(フランス、ハーラン)が、(それらから別のラットの光景を奪い、摂食を妨げないために)アルミニウムの格子によって閉じられた不透明な個別のケージに入れられる。それらは21±1°Cの温度に空調され、12時間(午後5時−午前7時)の昼夜周期の部屋に入れられる。それらは、食餌(完全食、フランスハーラン)及び水を順応期間(5日間)及び実験の最初の2週間自由に得た。
等価平均質量でグループを形成するために体重を測定された後、前記ラットは実験開始前の7日間の順応期間維持される。前記実験期間は最初の週の月曜日(D1)に開始し、2週間継続する。
第2週目の終わりに、前記ラットは、強制給餌30分後、断頭によって屠殺され、血液はチューブ/5% EDTAに試料採取される。その後、血漿の3つの分注液が以下の循環ホルモンを解析するために作成されるであろう。分注液1がGLP−1であり、分注液2がCCKである。
1 食物摂取
図8に示された結果は、食物のグラムと、それらの最初の体重とで、実験の2週間全体にわたって前記ラットに与えられた食物の消費量を示す。値は実験期間の各グループについて得られた毎日の値の平均であり、±標準偏差で示される。*はp値が0.05未満であり、**はp値が0.01未満である。
ラットの血漿中のCCK濃度がペーシュ・サン・マロ・サンテ社(Compagnie de Peches Saint Malo−Sante)によって開発された放射線免疫学的解析によって測定された。この解析は硫酸化した活性型CCKsに特異的抗体を用いる特殊性を有し、1998年に開発され(レーフェルド、1998)、該抗体は(CCKと比較してより多量に血漿中に存在する)ガストリンのさまざまな形状と交差しない。このプロトコルは、特に、同一の抗体を用いるIBL(IBL、ドイツハンブルク)によって配給される解析キットから開発された。血漿中の活性型のGLP−1濃度は、前記放射線免疫学的解析キット(GLP1A−35HK、リンコリサーチ、アメリカ合衆国ミズーリ州セントチャールズ)によって決定された。前記解析は販売業者によって提供された前記プロトコルに従って実施される。前記結果は、図9及び10で示される。GLP−1(図10)及びCCK(図9)の血漿濃度が血漿のpmol.L−1で示される。値は各グループの平均であり、±標準偏差で示される。*はT−検定でp値が0.05未満であり、**はT−検定でp値が0.01未満である。図9では、同一の文字を割り当てられていない平均値は異なる。
[1]Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005;128:175−191.
[2]Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G183−188.
[3]Moran TH. Cholecystokinin and satiety:current perspectives. Nutrition 2000;16:858−865.
[4]Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006;361:1187−209.
[5]Cuber JC, Bernard C, Levenez F, Chayvialle JA. [Lipids, proteins and carbohydrates stimulate the secretion of intestinal cholecystokinin in the pig]. Reprod Nutr Dev 1990;30:267−75.
[6]Baile CA, McLaughlin CL, Della−Fera MA. Role of cholecystokinin and opioid peptides in control of food intake. Physiol Rev 1986;66:172−234.
[7]Liddle RA, Green GM, Conrad CK, Williams JA. Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am J Physiol 1986;251:G243−8.
[8]Douglas BR, Woutersen RA, Jansen JBら、The influence of different nutrients on plasma cholecystokinin levels in the rat. Experientia 1988;44:21−3.
[9]Miazza B, Palma R, Lachance JRら、Jejunal secretory effect of intraduodenal food in humans. A comparison of mixed nutrients, proteins, lipids, and carbohydrates. Gastroenterology 1985;88:1215−22.
[10]Mangel AWら、Phenylalanine−stimulated secretion of cholecystokinin is calcium dependent. Am J Physiol, 1995. 268(1 Pt 1):p.G90−4.
[11]Brubaker PL, Izzo A, Rocca AS. Synthesis and secretion of intestinal proglucagon−derived peptides by the STC−1 enteroendocrine cell line. Can J Diabetes. 2003;27:141−148.
Claims (11)
- 魚類タンパク質の加水分解産物であって、該魚類タンパク質の加水分解産物が、ミクロメシスティウス・ポタソウ(Micromesistius poutassou)のタンパク質の供給源を酵素的加水分解することによって得られ、
該酵素的加水分解は、バチルス・アミロリクエファシエンス(Bacillus amyloliquefaciens)及びバチルス・リケニフォルミス(Bacillus licheniformis)由来のエンドペプチダーゼを含む酵素混合物であるプロタメックス(登録商標)(ノボザイム社製)によって行われること、
300Da未満の分子量の分子が23%から31%まで、300Daから1000Daまでの分子量の分子が31%から34%まで、1000Daから3000Daまでの分子量の分子が28%から34%まで、3000Daから5000Daまでの分子量の分子が6%から8%まで、及び、5000Daから10000Daまでの分子量の分子が2%から4%までと、
原産物の百分率として1%未満の脂質含有量と、
原産物の百分率として0.1%未満の糖質含有量と、
原産物の百分率として80%よりも多いタンパク質含有量と、
原産物の百分率として10%から20%までの無機質含有量との分子プロファイル分布を有すること、及び、
コレシストキニン、すなわち、CCKsに免疫学的に類似する分子を含むことを特徴とする、魚類タンパク質の加水分解産物。 - 前記魚類タンパク質の加水分解産物は、アミノ酸の総質量に関しての質量あたりの百分率として、グルタミン酸 17.4%、アスパラギン酸 11.4%、リジン 10.2%、ロイシン 8.4%、アルギニン 6.1%、アラニン 6.8%、バリン 4.7%、イソロイシン 4.2%、グリシン 5%、スレオニン 4.5%、セリン 4.4%、チロシン 3.2%、フェニルアラニン 3.9%、メチオニン 2.5%、プロリン 3.6%、ヒスチジン 1.9%、システイン 1%、トリプトファン 0.8%のアミノ酸組成を有することを特徴とする、請求項1に記載の魚類タンパク質の加水分解産物。
- 魚類タンパク質の前記供給源は前記魚類の切り身から得られたすり身を含むことを特徴とする、請求項1又は2に記載の魚類タンパク質の加水分解産物。
- 前記魚類からすり身を回収するために、水の存在下で、ミクロメシスティウス・ポタソウ(Micromesistius poutassou)のタンパク質の供給源をすりつぶすステップと、
反応混合物を得るために、タンパク質の供給源に対して酵素の割合が0.01%から2%までで、バチルス・アミロリクエファシエンス(Bacillus amyloliquefaciens)及びバチルス・リケニフォルミス(Bacillus licheniformis)由来のエンドペプチダーゼを含む酵素混合物であるプロタメックス(登録商標)(ノボザイム社製)の添加後、1時間ないし5時間、40°Cから65°Cまでの温度、pH6からpH9までの範囲のpHで前記タンパク質の供給源を酵素的加水分解するステップと、
前記反応混合物の温度を70°Cを下回らないレベルに8ないし20分間上昇させた後、前記酵素を不活性化することによって前記酵素的加水分解を停止するステップと、
前記反応混合物の残余から得られた前記タンパク質の加水分解産物を分離するステップとを含むことを特徴とする、請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物の製造方法。 - タンパク質供給源に対する酵素の割合が0.5%であり、前記加水分解温度は60°Cであり、前記pHは7.5であることを特徴とする、請求項4に記載の方法。
- 請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物を含むことを特徴とする、組成物。
- 請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物を含むことを特徴とする、補助栄養食品。
- 請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物を含むことを特徴とする、医薬品組成物。
- 肥満、2型糖尿病、高血圧、アテローム性動脈硬化症又は高コレステロール血症の治療か、循環器障害の予防かで使用するための請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物。
- CCK分子及び/又はGLP1分子の分泌の促進で使用するための請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物。
- 満腹の制御で使用するための請求項1ないし3の1つに記載の魚類タンパク質の加水分解産物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR08/00751 | 2008-02-12 | ||
FR0800751A FR2927335B1 (fr) | 2008-02-12 | 2008-02-12 | Hydrolysat de proteines de poissons presentant une activite satietogene, compositions nutraceutiques et pharmacologiques comprenant un tel hydrolysat et procede d'obtention |
PCT/EP2009/051638 WO2009101134A1 (fr) | 2008-02-12 | 2009-02-12 | Hydrolysat de proteines de poissons presentant une activite satietogene, compositions nutraceutiques et pharmacologiques comprenant un tel hydrolysat et procede d'obtention |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011512330A JP2011512330A (ja) | 2011-04-21 |
JP5828638B2 true JP5828638B2 (ja) | 2015-12-09 |
Family
ID=39865252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010545508A Active JP5828638B2 (ja) | 2008-02-12 | 2009-02-12 | 満腹活性を有する魚類タンパク質の加水分解産物、該加水分解産物を含む栄養補助食品及び医薬品の組成物、及び、その製造方法。 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20110039768A1 (ja) |
EP (1) | EP2247744B1 (ja) |
JP (1) | JP5828638B2 (ja) |
CA (1) | CA2714128A1 (ja) |
ES (1) | ES2590454T3 (ja) |
FR (1) | FR2927335B1 (ja) |
WO (1) | WO2009101134A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2927336B1 (fr) | 2008-02-12 | 2010-05-21 | Cie Des Peches Saint Malo Sant | Hydrolysat de proteines de poissons presentant une activite de stimulation et de maintien du capital osseux, compositions nutraceutiques et pharmacologiques comprenant un tel hydrolysat et procede d'obtention |
FR2947149B1 (fr) * | 2009-06-26 | 2011-09-09 | Cie Des Peches Saint Malo Sante | Hydrolysat de proteines de poissons pour son utilisation dans l'inhibition de la prise de poids et/ou la perte de poids |
NO20100359A1 (no) * | 2010-03-08 | 2011-09-09 | Marine Bioproducts As | Peptidmateriale og preparater og anvendelser derav. |
NO20100370A1 (no) * | 2010-03-08 | 2011-09-09 | Marine Bioproducts As | Peptidmateriale, fôrsammensetninger og preparater, og anvendelser derav. |
NO20100369A1 (no) * | 2010-03-08 | 2011-09-09 | Marine Bioproducts As | Peptidmateriale, fôrsammensetning og preparater og anvendelser derav. |
EP2677885A1 (en) * | 2011-02-23 | 2014-01-01 | Solae, Llc | Protein hydrolysate compositions having enhanced cck and glp-1 releasing activity |
FR2979542B1 (fr) * | 2011-09-06 | 2014-03-14 | Cie Des Peches Saint Malo Sante | Hydrolysats de proteines de poisson pour leur utilisation dans la prevention et/ou le traitement de troubles metaboliques tels qu'un syndrome metabolique, en particulier associe a l'obesite. |
RU2472517C1 (ru) * | 2012-02-01 | 2013-01-20 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Способ получения пептидного комплекса из печени рыб тресковых пород |
KR101403325B1 (ko) | 2012-06-19 | 2014-06-05 | (주)청룡수산 | 조기 비늘의 효소적 가수분해물을 유효성분으로 포함하는 고혈압의 예방 또는 치료용 약학적 조성물 |
EP2948003B1 (en) | 2013-01-23 | 2020-03-18 | Bottled Science Limited | Skin enhancing beverage composition |
MX2016008880A (es) * | 2014-01-08 | 2016-11-30 | Firmenich & Cie | Emulsiones de peptidos marinos. |
US10213473B2 (en) * | 2014-07-31 | 2019-02-26 | Firmenich Sa | Marine peptides and nucleotides |
EP3316700A1 (en) * | 2015-06-30 | 2018-05-09 | Firmenich SA | Marine peptides and muscle health |
EP3397078A1 (en) | 2015-12-28 | 2018-11-07 | Abbott Laboratories | Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof |
CN107459570A (zh) * | 2017-07-11 | 2017-12-12 | 浙江丰宇海洋生物制品有限公司 | 一种功能性蛋白肽产品 |
WO2019245380A1 (en) * | 2018-06-20 | 2019-12-26 | Hofseth Biocare Asa | Fish protein hydrolysate powder and a composition comprising said powder for use as a medicament |
CN114671943B (zh) * | 2022-04-29 | 2023-05-05 | 四川大学 | 一种鱼类摄食调控蛋白的制备和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59161319A (ja) * | 1983-03-04 | 1984-09-12 | Nippon Bussan Kk | 薬理作用を有する魚貝類エキスの製造方法 |
PE20040320A1 (es) * | 2002-08-14 | 2004-06-26 | Novozymes As | Composicion alimenticia que comprende hidrolizado de proteinas de pescado y metodo para obtenerla |
NO322425B1 (no) * | 2003-07-04 | 2006-10-02 | Berge Biomed As | Anvendelse av et hydrolysat av proteinholdig fiskemateriale for fremstilling av et farmasoytisk middel for behandling og/eller hindring av patologisk hoye nivaer av tracylglyceroler, hyperkolesterolemia, hyperhomocysteinemia, eller patologisk lave nivaer av beta-oksidasjon i et dyr eller menneske. |
US20090111747A1 (en) * | 2005-02-14 | 2009-04-30 | Harry Stephen Ewart | Anti-Diabetic or Anti-Hypertensive Dietary Supplement |
-
2008
- 2008-02-12 FR FR0800751A patent/FR2927335B1/fr not_active Expired - Fee Related
-
2009
- 2009-02-12 WO PCT/EP2009/051638 patent/WO2009101134A1/fr active Application Filing
- 2009-02-12 US US12/866,878 patent/US20110039768A1/en not_active Abandoned
- 2009-02-12 ES ES09710311.3T patent/ES2590454T3/es active Active
- 2009-02-12 EP EP09710311.3A patent/EP2247744B1/fr active Active
- 2009-02-12 JP JP2010545508A patent/JP5828638B2/ja active Active
- 2009-02-12 CA CA2714128A patent/CA2714128A1/en not_active Abandoned
-
2013
- 2013-11-20 US US14/085,350 patent/US20150025001A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110039768A1 (en) | 2011-02-17 |
EP2247744B1 (fr) | 2016-06-08 |
ES2590454T3 (es) | 2016-11-22 |
CA2714128A1 (en) | 2009-08-20 |
JP2011512330A (ja) | 2011-04-21 |
WO2009101134A1 (fr) | 2009-08-20 |
EP2247744A1 (fr) | 2010-11-10 |
FR2927335A1 (fr) | 2009-08-14 |
US20150025001A1 (en) | 2015-01-22 |
FR2927335B1 (fr) | 2012-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5828638B2 (ja) | 満腹活性を有する魚類タンパク質の加水分解産物、該加水分解産物を含む栄養補助食品及び医薬品の組成物、及び、その製造方法。 | |
KR101331777B1 (ko) | Dpp-iv를 억제하는 펩타이드가 풍부한 단백질가수분해물 및 이의 용도 | |
Horner et al. | Bioavailability of milk protein-derived bioactive peptides: A glycaemic management perspective | |
CN101426513B (zh) | 含有肽作为有效成分的组合物 | |
Marambe et al. | Release of angiotensin I-converting enzyme inhibitory peptides from flaxseed (Linum usitatissimum L.) protein under simulated gastrointestinal digestion | |
JP5543375B2 (ja) | 骨の備蓄を促進し、維持する活性を有する魚類タンパク質の加水分解産物、該加水分解産物を含む栄養補助食品及び医薬品の組成物、及び、その製造方法。 | |
JP2009517464A (ja) | グルカゴン様ペプチド1の活性を増強するタンパク質加水分解物の使用 | |
Parthsarathy et al. | Boarfish (Capros aper) protein hydrolysate has potent insulinotropic and GLP‐1 secretory activity in vitro and acute glucose lowering effects in mice | |
JP7157043B2 (ja) | Glp-1分泌促進剤及び組成物 | |
McLaughlin et al. | Twice daily oral administration of Palmaria palmata protein hydrolysate reduces food intake in streptozotocin induced diabetic mice, improving glycaemic control and lipid profiles | |
JP5687697B2 (ja) | 体重増加の抑制及び/又は体重減少に使用するための魚類タンパク質の加水分解産物 | |
Yao et al. | Screening and identification of high bioavailable oligopeptides from rapeseed napin (Brassica napus) protein-derived hydrolysates via Caco-2/HepG2 co-culture model | |
PH12015502100B1 (en) | Reducing the risk of autoimmune disease | |
Pedroche et al. | Production of Brassica carinata protein hydrolyzates with a high Fischer's ratio using immobilized proteases | |
JPWO2006132273A1 (ja) | 摂食抑制作用を有するペプチドを含有する組成物 | |
Kondrashina et al. | Irish Cheddar cheese increases glucagon-like peptide-1 secretion in vitro but bioactivity is lost during gut transit | |
ES2329316A1 (es) | Obtencion y propiedades antihipertensivas de peptidos derivados de proteinas de clara de huevo. | |
JP4929455B2 (ja) | 摂食抑制作用を有する豚肉由来ペプチドを含有する組成物 | |
JP6994325B2 (ja) | 血中尿酸値低減剤及び血中尿酸値低減用組成物 | |
Jin Jr | Separation and purification of antidiabetic bioactive peptide from salmon and cod waste | |
WO2007069716A1 (ja) | 内臓脂肪蓄積抑制作用を有する組成物 | |
TW201125573A (en) | Glucagon-like peptide-1 secretion promoter | |
JP2024042331A (ja) | そばに由来するタンパク質の加水分解物を含むdppiv阻害剤 | |
TW201127391A (en) | Cholecystokinin secretion promoter | |
WO2023120363A1 (ja) | 血糖値上昇抑制用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140304 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20140424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140604 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150401 |
|
A59 | Written plea |
Free format text: JAPANESE INTERMEDIATE CODE: A59 Effective date: 20150421 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150728 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151020 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5828638 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |